| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder | 134 | 2019 | 320 | 20.220 |
Why?
|
| Urinary Bladder, Overactive | 47 | 2016 | 63 | 11.180 |
Why?
|
| Urination | 51 | 2018 | 69 | 8.220 |
Why?
|
| Urodynamics | 50 | 2018 | 88 | 6.310 |
Why?
|
| Muscle, Smooth | 49 | 2018 | 152 | 6.130 |
Why?
|
| Muscarinic Antagonists | 26 | 2016 | 38 | 5.450 |
Why?
|
| Urinary Bladder Diseases | 24 | 2017 | 44 | 5.260 |
Why?
|
| Animals | 208 | 2019 | 8196 | 4.980 |
Why?
|
| Urinary Bladder Neck Obstruction | 25 | 2017 | 30 | 4.390 |
Why?
|
| Rats | 103 | 2019 | 1895 | 4.130 |
Why?
|
| Rats, Sprague-Dawley | 78 | 2019 | 897 | 3.730 |
Why?
|
| Muscle Contraction | 39 | 2018 | 175 | 3.450 |
Why?
|
| Urethra | 23 | 2019 | 125 | 3.290 |
Why?
|
| Urinary Incontinence | 18 | 2018 | 68 | 3.140 |
Why?
|
| Ischemia | 11 | 2016 | 115 | 3.080 |
Why?
|
| Urination Disorders | 13 | 2014 | 17 | 2.900 |
Why?
|
| Disease Models, Animal | 44 | 2019 | 1081 | 2.770 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 12 | 2014 | 18 | 2.450 |
Why?
|
| Urinary Incontinence, Stress | 8 | 2019 | 75 | 2.390 |
Why?
|
| Humans | 183 | 2019 | 32262 | 2.370 |
Why?
|
| Erectile Dysfunction | 18 | 2018 | 69 | 2.340 |
Why?
|
| Prostate | 19 | 2019 | 88 | 2.220 |
Why?
|
| Female | 147 | 2019 | 19935 | 2.190 |
Why?
|
| Adrenergic alpha-Antagonists | 12 | 2010 | 35 | 2.130 |
Why?
|
| Acetanilides | 8 | 2017 | 12 | 2.110 |
Why?
|
| Thiazoles | 8 | 2017 | 36 | 2.090 |
Why?
|
| Prostatic Hyperplasia | 15 | 2018 | 59 | 2.070 |
Why?
|
| Urologic Diseases | 8 | 2017 | 35 | 1.970 |
Why?
|
| Spinal Cord Injuries | 6 | 2018 | 44 | 1.960 |
Why?
|
| Male | 141 | 2019 | 19429 | 1.890 |
Why?
|
| Regenerative Medicine | 7 | 2019 | 217 | 1.880 |
Why?
|
| Urethral Obstruction | 8 | 2012 | 12 | 1.800 |
Why?
|
| Adenosine Triphosphate | 12 | 2017 | 71 | 1.760 |
Why?
|
| Chemokine CXCL12 | 5 | 2019 | 27 | 1.760 |
Why?
|
| Myoblasts | 5 | 2017 | 41 | 1.640 |
Why?
|
| Urinary Bladder, Neurogenic | 11 | 2018 | 29 | 1.640 |
Why?
|
| Urethral Diseases | 3 | 2019 | 20 | 1.580 |
Why?
|
| Carbolines | 4 | 2014 | 6 | 1.520 |
Why?
|
| Penile Erection | 11 | 2016 | 31 | 1.510 |
Why?
|
| Receptors, Muscarinic | 11 | 2013 | 21 | 1.500 |
Why?
|
| Receptors, Adrenergic, beta-3 | 6 | 2017 | 12 | 1.490 |
Why?
|
| Afferent Pathways | 11 | 2016 | 40 | 1.470 |
Why?
|
| Urothelium | 12 | 2015 | 64 | 1.470 |
Why?
|
| Diabetes Mellitus, Experimental | 4 | 2019 | 64 | 1.440 |
Why?
|
| Oxidative Stress | 9 | 2019 | 255 | 1.410 |
Why?
|
| Mice | 44 | 2018 | 2571 | 1.370 |
Why?
|
| Receptors, Serotonin | 4 | 2018 | 10 | 1.320 |
Why?
|
| Benzhydryl Compounds | 6 | 2012 | 23 | 1.300 |
Why?
|
| Nocturia | 6 | 2019 | 7 | 1.300 |
Why?
|
| Tissue Engineering | 13 | 2017 | 695 | 1.180 |
Why?
|
| Receptor, Cannabinoid, CB2 | 6 | 2013 | 23 | 1.180 |
Why?
|
| Melatonin | 4 | 2016 | 8 | 1.180 |
Why?
|
| TRPM Cation Channels | 4 | 2015 | 8 | 1.180 |
Why?
|
| Pharmacology | 3 | 2016 | 6 | 1.160 |
Why?
|
| Sexual Dysfunction, Physiological | 7 | 2017 | 19 | 1.130 |
Why?
|
| Chronic Disease | 15 | 2019 | 413 | 1.120 |
Why?
|
| Immunohistochemistry | 21 | 2017 | 544 | 1.060 |
Why?
|
| Parkinson Disease | 4 | 2013 | 87 | 1.060 |
Why?
|
| Spinal Cord | 7 | 2019 | 137 | 1.020 |
Why?
|
| Ejaculation | 6 | 2011 | 7 | 0.980 |
Why?
|
| Piperazines | 7 | 2013 | 60 | 0.980 |
Why?
|
| Stem Cell Transplantation | 5 | 2016 | 221 | 0.970 |
Why?
|
| Neurotransmitter Agents | 6 | 2011 | 35 | 0.970 |
Why?
|
| Urinary Incontinence, Urge | 3 | 2014 | 5 | 0.970 |
Why?
|
| Signal Transduction | 16 | 2016 | 727 | 0.860 |
Why?
|
| Phosphodiesterase Inhibitors | 8 | 2010 | 17 | 0.860 |
Why?
|
| Muscle Relaxation | 7 | 2016 | 21 | 0.860 |
Why?
|
| Cold Temperature | 4 | 2013 | 57 | 0.850 |
Why?
|
| Heart Rate | 4 | 2011 | 364 | 0.820 |
Why?
|
| Neurons, Afferent | 8 | 2017 | 64 | 0.820 |
Why?
|
| Urinary Tract | 8 | 2017 | 31 | 0.810 |
Why?
|
| Central Nervous System Diseases | 4 | 2011 | 17 | 0.800 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 3 | 2019 | 8 | 0.790 |
Why?
|
| Dose-Response Relationship, Drug | 20 | 2016 | 716 | 0.780 |
Why?
|
| Penis | 10 | 2010 | 45 | 0.780 |
Why?
|
| Tramadol | 5 | 2016 | 5 | 0.770 |
Why?
|
| Adenosine | 3 | 2017 | 68 | 0.760 |
Why?
|
| Epidermal Growth Factor | 3 | 2011 | 25 | 0.760 |
Why?
|
| Terminology as Topic | 5 | 2014 | 68 | 0.760 |
Why?
|
| Sulfonamides | 7 | 2012 | 86 | 0.750 |
Why?
|
| Receptor, erbB-2 | 6 | 2013 | 63 | 0.750 |
Why?
|
| Indoles | 7 | 2013 | 65 | 0.750 |
Why?
|
| Cresols | 4 | 2012 | 5 | 0.740 |
Why?
|
| Receptor, Cannabinoid, CB1 | 3 | 2014 | 68 | 0.740 |
Why?
|
| Practice Guidelines as Topic | 4 | 2013 | 395 | 0.720 |
Why?
|
| Aging | 8 | 2017 | 942 | 0.710 |
Why?
|
| Imidazoles | 4 | 2014 | 97 | 0.710 |
Why?
|
| Doxazosin | 3 | 2010 | 5 | 0.700 |
Why?
|
| Mucous Membrane | 5 | 2014 | 27 | 0.700 |
Why?
|
| Pressure | 17 | 2017 | 69 | 0.690 |
Why?
|
| Motor Neurons | 3 | 2019 | 50 | 0.680 |
Why?
|
| Polyuria | 2 | 2018 | 4 | 0.670 |
Why?
|
| Dopamine Agonists | 4 | 2016 | 30 | 0.650 |
Why?
|
| Phosphoric Diester Hydrolases | 9 | 2007 | 18 | 0.650 |
Why?
|
| Deamino Arginine Vasopressin | 2 | 2019 | 2 | 0.650 |
Why?
|
| Dinoprostone | 6 | 2018 | 36 | 0.640 |
Why?
|
| Fibrosis | 2 | 2018 | 126 | 0.640 |
Why?
|
| Extracellular Matrix | 3 | 2018 | 256 | 0.640 |
Why?
|
| Calcitriol | 4 | 2012 | 29 | 0.620 |
Why?
|
| Nitric Oxide | 7 | 2010 | 121 | 0.600 |
Why?
|
| Atherosclerosis | 6 | 2016 | 821 | 0.600 |
Why?
|
| Antidiuretic Agents | 1 | 2019 | 1 | 0.600 |
Why?
|
| Receptors, Serotonin, 5-HT2 | 1 | 2019 | 1 | 0.590 |
Why?
|
| Enzyme Inhibitors | 7 | 2011 | 174 | 0.590 |
Why?
|
| Biocompatible Materials | 3 | 2016 | 240 | 0.580 |
Why?
|
| Endopeptidases | 3 | 2015 | 29 | 0.580 |
Why?
|
| Tachykinins | 3 | 2009 | 5 | 0.580 |
Why?
|
| Cyclic GMP | 10 | 2009 | 23 | 0.560 |
Why?
|
| Cystitis, Interstitial | 4 | 2017 | 57 | 0.550 |
Why?
|
| Treatment Outcome | 17 | 2017 | 3408 | 0.550 |
Why?
|
| TRPV Cation Channels | 4 | 2017 | 26 | 0.550 |
Why?
|
| Models, Biological | 5 | 2017 | 408 | 0.550 |
Why?
|
| Epithelial Cells | 3 | 2015 | 132 | 0.540 |
Why?
|
| Myocytes, Smooth Muscle | 4 | 2015 | 90 | 0.540 |
Why?
|
| Electric Stimulation | 12 | 2017 | 135 | 0.540 |
Why?
|
| Cardiovascular Diseases | 3 | 2011 | 1159 | 0.530 |
Why?
|
| Kidney | 4 | 2017 | 521 | 0.520 |
Why?
|
| Receptors, Purinergic P2 | 3 | 2009 | 11 | 0.520 |
Why?
|
| Vasodilator Agents | 3 | 2014 | 62 | 0.510 |
Why?
|
| Cyclic AMP | 7 | 2010 | 55 | 0.510 |
Why?
|
| Time Factors | 15 | 2016 | 2203 | 0.500 |
Why?
|
| Genitalia, Male | 1 | 2016 | 5 | 0.500 |
Why?
|
| Aged | 26 | 2019 | 10249 | 0.500 |
Why?
|
| RNA, Messenger | 5 | 2012 | 499 | 0.500 |
Why?
|
| Solvents | 2 | 2015 | 6 | 0.490 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 2016 | 9 | 0.490 |
Why?
|
| Urologic Surgical Procedures | 2 | 2014 | 66 | 0.490 |
Why?
|
| Quinuclidines | 2 | 2014 | 4 | 0.480 |
Why?
|
| Tetrahydroisoquinolines | 2 | 2014 | 4 | 0.480 |
Why?
|
| Neuromuscular Agents | 2 | 2015 | 36 | 0.480 |
Why?
|
| Adrenergic Agonists | 3 | 2013 | 8 | 0.480 |
Why?
|
| Nicotinamide-Nucleotide Adenylyltransferase | 2 | 2013 | 7 | 0.480 |
Why?
|
| Botulinum Toxins | 2 | 2015 | 30 | 0.480 |
Why?
|
| Drug Therapy, Combination | 7 | 2018 | 292 | 0.480 |
Why?
|
| Receptors, Prostaglandin E | 2 | 2007 | 6 | 0.470 |
Why?
|
| Cell Communication | 3 | 2010 | 37 | 0.460 |
Why?
|
| Superoxides | 2 | 2015 | 24 | 0.460 |
Why?
|
| Pelvis | 2 | 2018 | 67 | 0.450 |
Why?
|
| Carbachol | 11 | 2014 | 17 | 0.440 |
Why?
|
| rho-Associated Kinases | 5 | 2012 | 15 | 0.440 |
Why?
|
| Consciousness | 7 | 2012 | 7 | 0.440 |
Why?
|
| Mutation | 2 | 2015 | 497 | 0.430 |
Why?
|
| Quinazolines | 2 | 2011 | 35 | 0.430 |
Why?
|
| Adrenergic beta-Agonists | 5 | 2012 | 31 | 0.430 |
Why?
|
| Nitric Oxide Synthase | 6 | 2019 | 41 | 0.430 |
Why?
|
| Phenylpropanolamine | 3 | 2012 | 3 | 0.420 |
Why?
|
| Cell Line, Tumor | 10 | 2013 | 727 | 0.420 |
Why?
|
| Membrane Proteins | 3 | 2010 | 243 | 0.410 |
Why?
|
| Transient Receptor Potential Channels | 2 | 2010 | 4 | 0.410 |
Why?
|
| Pelvic Floor | 3 | 2017 | 23 | 0.410 |
Why?
|
| Collagen | 5 | 2017 | 229 | 0.410 |
Why?
|
| Blotting, Western | 12 | 2018 | 299 | 0.400 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2013 | 8 | 0.400 |
Why?
|
| Mice, Knockout | 7 | 2014 | 454 | 0.400 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 2 | 2011 | 4 | 0.390 |
Why?
|
| Bone Marrow | 1 | 2013 | 68 | 0.390 |
Why?
|
| Vascular Diseases | 1 | 2013 | 66 | 0.390 |
Why?
|
| Cerebral Infarction | 2 | 2003 | 25 | 0.390 |
Why?
|
| Indophenol | 1 | 2012 | 1 | 0.380 |
Why?
|
| Primates | 3 | 2019 | 128 | 0.380 |
Why?
|
| Pyridines | 8 | 2012 | 79 | 0.380 |
Why?
|
| Urology | 2 | 2010 | 33 | 0.380 |
Why?
|
| Drug Delivery Systems | 4 | 2011 | 104 | 0.380 |
Why?
|
| Antineoplastic Agents | 3 | 2013 | 595 | 0.380 |
Why?
|
| Macaca fascicularis | 7 | 2018 | 542 | 0.380 |
Why?
|
| Up-Regulation | 5 | 2017 | 193 | 0.380 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2013 | 73 | 0.380 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2014 | 191 | 0.370 |
Why?
|
| Models, Statistical | 1 | 2013 | 187 | 0.370 |
Why?
|
| Prostatic Neoplasms | 6 | 2016 | 489 | 0.370 |
Why?
|
| Stress, Physiological | 1 | 2012 | 57 | 0.370 |
Why?
|
| Serotonin | 3 | 2019 | 44 | 0.370 |
Why?
|
| Receptors, Adrenergic | 3 | 2017 | 13 | 0.370 |
Why?
|
| Mice, Inbred C57BL | 11 | 2018 | 792 | 0.360 |
Why?
|
| Capsaicin | 5 | 2010 | 31 | 0.360 |
Why?
|
| Dexmedetomidine | 2 | 2014 | 12 | 0.360 |
Why?
|
| Middle Aged | 26 | 2019 | 11837 | 0.350 |
Why?
|
| Receptors, Prostaglandin | 2 | 2009 | 5 | 0.350 |
Why?
|
| Peer Review, Research | 1 | 2011 | 11 | 0.340 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 763 | 0.340 |
Why?
|
| Antibodies | 2 | 2013 | 56 | 0.340 |
Why?
|
| Analgesics, Opioid | 2 | 2003 | 251 | 0.340 |
Why?
|
| Biochemistry | 1 | 2011 | 1 | 0.340 |
Why?
|
| Cannabinol | 1 | 2010 | 1 | 0.330 |
Why?
|
| Pelvic Organ Prolapse | 1 | 2011 | 48 | 0.330 |
Why?
|
| Mechanotransduction, Cellular | 2 | 2011 | 13 | 0.330 |
Why?
|
| Disease Management | 1 | 2011 | 129 | 0.330 |
Why?
|
| Publishing | 1 | 2011 | 66 | 0.330 |
Why?
|
| Diterpenes | 4 | 2010 | 22 | 0.330 |
Why?
|
| Blood Pressure | 4 | 2009 | 864 | 0.320 |
Why?
|
| Antioxidants | 4 | 2017 | 122 | 0.320 |
Why?
|
| Heart Diseases | 1 | 2011 | 114 | 0.320 |
Why?
|
| Connexin 43 | 3 | 2014 | 7 | 0.310 |
Why?
|
| Urine | 5 | 2017 | 69 | 0.310 |
Why?
|
| Reference Values | 6 | 2017 | 238 | 0.310 |
Why?
|
| Receptors, Thromboxane | 1 | 2009 | 2 | 0.310 |
Why?
|
| Receptor, Muscarinic M3 | 3 | 2008 | 3 | 0.310 |
Why?
|
| Stem Cells | 4 | 2015 | 321 | 0.300 |
Why?
|
| Naphthalenes | 2 | 2009 | 53 | 0.300 |
Why?
|
| Injections, Spinal | 4 | 2018 | 119 | 0.300 |
Why?
|
| Pharmacogenetics | 1 | 2009 | 29 | 0.300 |
Why?
|
| Central Nervous System Agents | 2 | 2012 | 4 | 0.300 |
Why?
|
| Protein Binding | 5 | 2016 | 244 | 0.300 |
Why?
|
| Apomorphine | 3 | 2005 | 10 | 0.290 |
Why?
|
| Receptor, Muscarinic M2 | 2 | 2008 | 4 | 0.290 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2016 | 257 | 0.290 |
Why?
|
| Genomics | 1 | 2009 | 89 | 0.290 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2009 | 7 | 0.290 |
Why?
|
| Evidence-Based Medicine | 5 | 2012 | 212 | 0.290 |
Why?
|
| Interstitial Cells of Cajal | 3 | 2014 | 4 | 0.290 |
Why?
|
| Organ Size | 6 | 2017 | 221 | 0.290 |
Why?
|
| Cannabinoids | 3 | 2016 | 56 | 0.280 |
Why?
|
| Risk Factors | 8 | 2017 | 3933 | 0.280 |
Why?
|
| Natriuretic Peptides | 1 | 2008 | 1 | 0.280 |
Why?
|
| Lumbosacral Region | 2 | 2019 | 11 | 0.280 |
Why?
|
| Muscle Fibers, Skeletal | 4 | 2016 | 108 | 0.280 |
Why?
|
| Injections, Intravenous | 3 | 2017 | 99 | 0.280 |
Why?
|
| Meningomyelocele | 1 | 2008 | 9 | 0.280 |
Why?
|
| Urinary Catheterization | 7 | 2018 | 22 | 0.270 |
Why?
|
| Central Nervous System | 2 | 2010 | 47 | 0.270 |
Why?
|
| Skin | 1 | 2010 | 212 | 0.270 |
Why?
|
| Prognosis | 7 | 2016 | 1529 | 0.270 |
Why?
|
| Regeneration | 4 | 2015 | 178 | 0.270 |
Why?
|
| Adult | 16 | 2019 | 9252 | 0.270 |
Why?
|
| Flow Cytometry | 4 | 2017 | 184 | 0.260 |
Why?
|
| Electromyography | 5 | 2013 | 67 | 0.260 |
Why?
|
| Receptors, Adrenergic, beta-2 | 2 | 2011 | 25 | 0.260 |
Why?
|
| Urogenital System | 1 | 2007 | 11 | 0.260 |
Why?
|
| Receptor, Serotonin, 5-HT2C | 2 | 2019 | 7 | 0.260 |
Why?
|
| Age Factors | 8 | 2016 | 1178 | 0.260 |
Why?
|
| Pharmacology, Clinical | 1 | 2007 | 1 | 0.250 |
Why?
|
| Prazosin | 2 | 2009 | 11 | 0.250 |
Why?
|
| Brain | 4 | 2012 | 966 | 0.250 |
Why?
|
| Drug Industry | 1 | 2007 | 16 | 0.250 |
Why?
|
| Injections | 4 | 2018 | 72 | 0.250 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 3893 | 0.250 |
Why?
|
| Vas Deferens | 2 | 2007 | 2 | 0.250 |
Why?
|
| Oximes | 1 | 2006 | 7 | 0.250 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2013 | 120 | 0.250 |
Why?
|
| Cell Culture Techniques | 2 | 2013 | 170 | 0.250 |
Why?
|
| Movement | 2 | 2004 | 61 | 0.240 |
Why?
|
| Random Allocation | 4 | 2017 | 247 | 0.240 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2004 | 82 | 0.240 |
Why?
|
| Circadian Rhythm | 2 | 2017 | 48 | 0.240 |
Why?
|
| Cystectomy | 4 | 2015 | 109 | 0.240 |
Why?
|
| Radioisotope Dilution Technique | 1 | 2006 | 1 | 0.240 |
Why?
|
| Fellowships and Scholarships | 1 | 2007 | 51 | 0.240 |
Why?
|
| Serotonin Antagonists | 2 | 2004 | 9 | 0.240 |
Why?
|
| Receptors, Thromboxane A2, Prostaglandin H2 | 3 | 2016 | 4 | 0.240 |
Why?
|
| Radioimmunoassay | 1 | 2006 | 25 | 0.240 |
Why?
|
| Antigens, Surface | 1 | 2006 | 24 | 0.240 |
Why?
|
| Swine | 7 | 2017 | 228 | 0.240 |
Why?
|
| Calcium | 6 | 2014 | 339 | 0.240 |
Why?
|
| Benzylamines | 1 | 2006 | 6 | 0.240 |
Why?
|
| Hypertension | 3 | 2010 | 980 | 0.240 |
Why?
|
| Guinea Pigs | 4 | 2011 | 16 | 0.230 |
Why?
|
| Acetylcholine | 2 | 2013 | 69 | 0.230 |
Why?
|
| Streptozocin | 2 | 2019 | 12 | 0.230 |
Why?
|
| Gene Expression Regulation | 4 | 2017 | 478 | 0.230 |
Why?
|
| Robotics | 2 | 2012 | 133 | 0.230 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2006 | 41 | 0.230 |
Why?
|
| Kinetics | 4 | 2015 | 250 | 0.230 |
Why?
|
| GABA Agonists | 2 | 2002 | 11 | 0.230 |
Why?
|
| Pelvic Pain | 2 | 2017 | 19 | 0.230 |
Why?
|
| Sensory Receptor Cells | 4 | 2012 | 35 | 0.230 |
Why?
|
| Procaterol | 2 | 2002 | 2 | 0.230 |
Why?
|
| Mice, Inbred BALB C | 7 | 2017 | 196 | 0.230 |
Why?
|
| Dioxoles | 2 | 2002 | 4 | 0.230 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2016 | 22 | 0.230 |
Why?
|
| Carcinoma | 1 | 2006 | 92 | 0.230 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2006 | 99 | 0.220 |
Why?
|
| Ion Channels | 3 | 2017 | 26 | 0.220 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2004 | 13 | 0.220 |
Why?
|
| Urinary Tract Physiological Phenomena | 2 | 2016 | 5 | 0.220 |
Why?
|
| Phenylenediamines | 1 | 2004 | 2 | 0.220 |
Why?
|
| Carbamates | 1 | 2004 | 16 | 0.220 |
Why?
|
| Elastin | 2 | 2017 | 16 | 0.220 |
Why?
|
| Gene Expression | 5 | 2018 | 346 | 0.220 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2004 | 5 | 0.210 |
Why?
|
| Cholesterol, Dietary | 2 | 2016 | 40 | 0.210 |
Why?
|
| Muscle, Skeletal | 3 | 2013 | 520 | 0.210 |
Why?
|
| Caloric Restriction | 2 | 2016 | 92 | 0.210 |
Why?
|
| Drugs, Investigational | 2 | 2016 | 9 | 0.210 |
Why?
|
| Guanosine Triphosphate | 1 | 2004 | 11 | 0.210 |
Why?
|
| Reflex | 2 | 2012 | 20 | 0.210 |
Why?
|
| Dopamine | 3 | 2016 | 262 | 0.210 |
Why?
|
| Cancer Vaccines | 2 | 2016 | 27 | 0.210 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2004 | 20 | 0.210 |
Why?
|
| Amines | 1 | 2004 | 23 | 0.200 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2004 | 49 | 0.200 |
Why?
|
| Clinical Trials as Topic | 4 | 2018 | 312 | 0.200 |
Why?
|
| Norepinephrine | 4 | 2012 | 101 | 0.200 |
Why?
|
| Ethanol | 3 | 2018 | 195 | 0.200 |
Why?
|
| Cell Proliferation | 5 | 2016 | 601 | 0.200 |
Why?
|
| Thromboxane A2 | 2 | 2016 | 4 | 0.200 |
Why?
|
| Receptors, Neurokinin-1 | 2 | 2018 | 5 | 0.200 |
Why?
|
| Amides | 6 | 2010 | 24 | 0.200 |
Why?
|
| Adolescent | 8 | 2019 | 3509 | 0.200 |
Why?
|
| Administration, Intravesical | 5 | 2010 | 28 | 0.200 |
Why?
|
| Acetic Acid | 1 | 2003 | 3 | 0.200 |
Why?
|
| Sulfones | 4 | 2014 | 23 | 0.200 |
Why?
|
| Membrane Glycoproteins | 2 | 2017 | 111 | 0.190 |
Why?
|
| Oxytocin | 2 | 2010 | 29 | 0.190 |
Why?
|
| Receptors, Estrogen | 1 | 2003 | 104 | 0.190 |
Why?
|
| Benzoates | 1 | 2002 | 7 | 0.190 |
Why?
|
| Oxyhemoglobins | 1 | 2002 | 9 | 0.190 |
Why?
|
| Calcium Signaling | 3 | 2012 | 49 | 0.190 |
Why?
|
| Receptors, GABA-B | 1 | 2002 | 19 | 0.190 |
Why?
|
| Administration, Oral | 3 | 2009 | 200 | 0.190 |
Why?
|
| Nerve Fibers, Unmyelinated | 5 | 2017 | 9 | 0.190 |
Why?
|
| Benzopyrans | 1 | 2002 | 7 | 0.190 |
Why?
|
| Organophosphorus Compounds | 1 | 2002 | 30 | 0.190 |
Why?
|
| Reflex, Abnormal | 1 | 2002 | 1 | 0.190 |
Why?
|
| RNA | 2 | 2014 | 94 | 0.190 |
Why?
|
| Nipecotic Acids | 1 | 2002 | 1 | 0.180 |
Why?
|
| Oleic Acids | 2 | 2012 | 9 | 0.180 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 1 | 2002 | 6 | 0.180 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 2002 | 3 | 0.180 |
Why?
|
| Indazoles | 1 | 2002 | 4 | 0.180 |
Why?
|
| Enzyme Activators | 1 | 2002 | 8 | 0.180 |
Why?
|
| Carbon Monoxide | 1 | 2002 | 10 | 0.180 |
Why?
|
| Oxidopamine | 2 | 2013 | 24 | 0.180 |
Why?
|
| alpha-MSH | 1 | 2002 | 2 | 0.180 |
Why?
|
| Sensation | 2 | 2014 | 60 | 0.180 |
Why?
|
| Adipose Tissue | 2 | 2015 | 320 | 0.180 |
Why?
|
| Phosphorylation | 7 | 2014 | 250 | 0.170 |
Why?
|
| Down-Regulation | 2 | 2014 | 131 | 0.170 |
Why?
|
| Neurotoxins | 3 | 2011 | 16 | 0.170 |
Why?
|
| Arteries | 2 | 2016 | 75 | 0.170 |
Why?
|
| Prostatectomy | 2 | 2019 | 85 | 0.170 |
Why?
|
| Disease Progression | 2 | 2013 | 591 | 0.160 |
Why?
|
| Estradiol | 3 | 2016 | 139 | 0.160 |
Why?
|
| Pilot Projects | 4 | 2014 | 553 | 0.160 |
Why?
|
| Young Adult | 3 | 2019 | 2643 | 0.160 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 4 | 2007 | 5 | 0.160 |
Why?
|
| Urinary Retention | 3 | 2005 | 10 | 0.150 |
Why?
|
| Connexins | 2 | 2017 | 10 | 0.150 |
Why?
|
| Sensitivity and Specificity | 5 | 2015 | 556 | 0.150 |
Why?
|
| Cytokines | 3 | 2016 | 237 | 0.150 |
Why?
|
| Receptors, Cannabinoid | 2 | 2010 | 33 | 0.150 |
Why?
|
| Injections, Intralesional | 1 | 2019 | 16 | 0.150 |
Why?
|
| Biological Availability | 1 | 2019 | 22 | 0.150 |
Why?
|
| Phenylephrine | 4 | 2014 | 34 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2016 | 246 | 0.150 |
Why?
|
| Rats, Inbred F344 | 6 | 2016 | 151 | 0.150 |
Why?
|
| Receptors, Drug | 3 | 2004 | 19 | 0.150 |
Why?
|
| Administration, Intranasal | 1 | 2019 | 35 | 0.150 |
Why?
|
| Triazines | 2 | 2009 | 8 | 0.150 |
Why?
|
| Quality of Life | 3 | 2017 | 968 | 0.150 |
Why?
|
| Nerve Tissue | 1 | 2019 | 4 | 0.150 |
Why?
|
| Transcriptional Activation | 1 | 2019 | 46 | 0.150 |
Why?
|
| Chromatography, Liquid | 1 | 2019 | 33 | 0.150 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2019 | 25 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 2 | 2014 | 245 | 0.140 |
Why?
|
| Gap Junctions | 3 | 2010 | 8 | 0.140 |
Why?
|
| Neuroepithelial Cells | 1 | 2018 | 1 | 0.140 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 98 | 0.140 |
Why?
|
| Cystitis | 1 | 2018 | 8 | 0.140 |
Why?
|
| Pain | 2 | 2018 | 302 | 0.140 |
Why?
|
| Relaxin | 1 | 2018 | 4 | 0.140 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 4 | 2013 | 4 | 0.140 |
Why?
|
| Ganglia, Spinal | 2 | 2016 | 59 | 0.140 |
Why?
|
| Iliac Artery | 3 | 2013 | 50 | 0.140 |
Why?
|
| Substance Abuse Detection | 1 | 2018 | 9 | 0.140 |
Why?
|
| Calcium Channels | 2 | 2010 | 63 | 0.140 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2016 | 7 | 0.140 |
Why?
|
| Receptors, Purinergic P1 | 1 | 2018 | 11 | 0.140 |
Why?
|
| Piperidines | 2 | 2014 | 137 | 0.140 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2011 | 8 | 0.140 |
Why?
|
| Ovarian Neoplasms | 3 | 2013 | 84 | 0.140 |
Why?
|
| Cholinergic Agonists | 3 | 2013 | 7 | 0.140 |
Why?
|
| Reactive Nitrogen Species | 1 | 2017 | 5 | 0.130 |
Why?
|
| Benzimidazoles | 2 | 2011 | 31 | 0.130 |
Why?
|
| Autophagy | 1 | 2018 | 55 | 0.130 |
Why?
|
| Pharmaceutical Preparations | 2 | 2009 | 38 | 0.130 |
Why?
|
| Cell Differentiation | 3 | 2015 | 461 | 0.130 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2017 | 10 | 0.130 |
Why?
|
| Blood Cell Count | 1 | 2017 | 28 | 0.130 |
Why?
|
| Cholinergic Agents | 1 | 2017 | 9 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2008 | 160 | 0.130 |
Why?
|
| Alcoholism | 1 | 2018 | 97 | 0.130 |
Why?
|
| Mechanical Phenomena | 1 | 2017 | 29 | 0.130 |
Why?
|
| Collagen Type III | 1 | 2017 | 9 | 0.130 |
Why?
|
| Electric Stimulation Therapy | 2 | 2018 | 19 | 0.130 |
Why?
|
| Nerve Growth Factor | 1 | 2017 | 5 | 0.130 |
Why?
|
| Nucleotide Transport Proteins | 1 | 2017 | 1 | 0.130 |
Why?
|
| Receptors, Purinergic | 3 | 2017 | 3 | 0.130 |
Why?
|
| Remission Induction | 1 | 2017 | 92 | 0.130 |
Why?
|
| Liver | 2 | 2017 | 492 | 0.130 |
Why?
|
| Absorbable Implants | 1 | 2017 | 24 | 0.130 |
Why?
|
| Abdominal Wall | 1 | 2017 | 24 | 0.130 |
Why?
|
| Collagen Type I | 1 | 2017 | 44 | 0.130 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 163 | 0.130 |
Why?
|
| Rats, Inbred SHR | 4 | 2010 | 35 | 0.130 |
Why?
|
| Fecal Incontinence | 1 | 2017 | 32 | 0.130 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 274 | 0.120 |
Why?
|
| Ovariectomy | 3 | 2012 | 202 | 0.120 |
Why?
|
| Case-Control Studies | 3 | 2015 | 854 | 0.120 |
Why?
|
| Patient Compliance | 1 | 2018 | 206 | 0.120 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 77 | 0.120 |
Why?
|
| CLOCK Proteins | 1 | 2016 | 2 | 0.120 |
Why?
|
| Drug Combinations | 2 | 2009 | 102 | 0.120 |
Why?
|
| Regional Blood Flow | 2 | 2013 | 85 | 0.120 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2016 | 11 | 0.120 |
Why?
|
| Lutetium | 2 | 2007 | 3 | 0.120 |
Why?
|
| Social Behavior | 1 | 2017 | 69 | 0.120 |
Why?
|
| Radioisotopes | 2 | 2007 | 8 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2016 | 30 | 0.120 |
Why?
|
| Chemokines | 1 | 2016 | 34 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 276 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2016 | 31 | 0.120 |
Why?
|
| Neurons, Efferent | 1 | 2016 | 2 | 0.120 |
Why?
|
| Synaptic Transmission | 1 | 2017 | 124 | 0.120 |
Why?
|
| Ligands | 3 | 2013 | 90 | 0.120 |
Why?
|
| Technetium | 2 | 2013 | 7 | 0.120 |
Why?
|
| Fibronectins | 2 | 2017 | 39 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 58 | 0.120 |
Why?
|
| Models, Animal | 3 | 2014 | 188 | 0.120 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 4 | 2009 | 5 | 0.120 |
Why?
|
| Prostatism | 1 | 2016 | 4 | 0.120 |
Why?
|
| Thromboplastin | 1 | 2016 | 1 | 0.120 |
Why?
|
| Chorionic Villi | 1 | 2016 | 8 | 0.120 |
Why?
|
| Nerve Fibers, Myelinated | 4 | 2017 | 27 | 0.120 |
Why?
|
| Muscle Relaxants, Central | 3 | 2006 | 10 | 0.120 |
Why?
|
| Drug Discovery | 2 | 2013 | 38 | 0.120 |
Why?
|
| Isometric Contraction | 3 | 2017 | 28 | 0.120 |
Why?
|
| Microscopy, Confocal | 2 | 2013 | 74 | 0.120 |
Why?
|
| Forecasting | 4 | 2018 | 144 | 0.110 |
Why?
|
| Staining and Labeling | 2 | 2013 | 63 | 0.110 |
Why?
|
| Mice, Inbred Strains | 3 | 2006 | 55 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 99 | 0.110 |
Why?
|
| Vagina | 2 | 2006 | 61 | 0.110 |
Why?
|
| Rats, Nude | 2 | 2013 | 48 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2018 | 544 | 0.110 |
Why?
|
| Bombesin | 2 | 2013 | 4 | 0.110 |
Why?
|
| Hypertrophy | 2 | 2006 | 33 | 0.110 |
Why?
|
| Protein Kinase C | 3 | 2012 | 43 | 0.110 |
Why?
|
| Comorbidity | 3 | 2012 | 563 | 0.110 |
Why?
|
| Receptor, erbB-3 | 1 | 2015 | 1 | 0.110 |
Why?
|
| Neuregulin-1 | 1 | 2015 | 2 | 0.110 |
Why?
|
| Colon | 2 | 2013 | 72 | 0.110 |
Why?
|
| Body Weight | 1 | 2017 | 323 | 0.110 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 34 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 854 | 0.110 |
Why?
|
| Superoxide Dismutase | 1 | 2015 | 41 | 0.110 |
Why?
|
| Platelet Factor 3 | 1 | 2014 | 1 | 0.110 |
Why?
|
| Free Radical Scavengers | 1 | 2014 | 14 | 0.110 |
Why?
|
| Erythropoietin | 1 | 2015 | 31 | 0.110 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2014 | 8 | 0.110 |
Why?
|
| Sexual Behavior, Animal | 2 | 2018 | 11 | 0.110 |
Why?
|
| Menthol | 2 | 2015 | 5 | 0.110 |
Why?
|
| Substance P | 2 | 2018 | 22 | 0.110 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2014 | 4 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 63 | 0.110 |
Why?
|
| Prevalence | 2 | 2014 | 955 | 0.110 |
Why?
|
| Receptors, Neurokinin-2 | 2 | 2006 | 2 | 0.110 |
Why?
|
| Ethanolamines | 2 | 2011 | 10 | 0.110 |
Why?
|
| Radiopharmaceuticals | 2 | 2013 | 95 | 0.110 |
Why?
|
| Wakefulness | 3 | 2017 | 25 | 0.110 |
Why?
|
| Fluorescent Dyes | 1 | 2014 | 52 | 0.110 |
Why?
|
| Creatinine | 1 | 2015 | 191 | 0.110 |
Why?
|
| Receptors, Tachykinin | 2 | 2006 | 2 | 0.110 |
Why?
|
| Injections, Intraventricular | 3 | 2005 | 16 | 0.110 |
Why?
|
| Chronobiology Disorders | 1 | 2014 | 1 | 0.110 |
Why?
|
| Vimentin | 1 | 2014 | 10 | 0.100 |
Why?
|
| Species Specificity | 2 | 2011 | 98 | 0.100 |
Why?
|
| Isoenzymes | 4 | 2006 | 67 | 0.100 |
Why?
|
| Ureter | 1 | 2014 | 39 | 0.100 |
Why?
|
| Antigen-Antibody Complex | 1 | 2013 | 5 | 0.100 |
Why?
|
| Body Temperature | 2 | 2015 | 20 | 0.100 |
Why?
|
| Radioligand Assay | 1 | 2013 | 24 | 0.100 |
Why?
|
| Mice, Mutant Strains | 2 | 2012 | 49 | 0.100 |
Why?
|
| Phthalic Acids | 1 | 2013 | 1 | 0.100 |
Why?
|
| Prostaglandin Antagonists | 1 | 2013 | 1 | 0.100 |
Why?
|
| Thromboxanes | 1 | 2013 | 1 | 0.100 |
Why?
|
| Peripheral Nerves | 1 | 2014 | 60 | 0.100 |
Why?
|
| Substantia Nigra | 1 | 2013 | 20 | 0.100 |
Why?
|
| Lymphatic Vessels | 1 | 2013 | 7 | 0.100 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2013 | 37 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2014 | 77 | 0.100 |
Why?
|
| Radionuclide Imaging | 3 | 2012 | 26 | 0.100 |
Why?
|
| Sensory System Agents | 2 | 2010 | 9 | 0.100 |
Why?
|
| Prospective Studies | 4 | 2019 | 2315 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2018 | 818 | 0.100 |
Why?
|
| Injections, Intraperitoneal | 2 | 2010 | 45 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 89 | 0.100 |
Why?
|
| Antibody Specificity | 2 | 2010 | 17 | 0.100 |
Why?
|
| Gene Expression Profiling | 3 | 2011 | 315 | 0.100 |
Why?
|
| Neurites | 1 | 2013 | 10 | 0.100 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2013 | 7 | 0.100 |
Why?
|
| Receptors, Endothelin | 2 | 2003 | 5 | 0.100 |
Why?
|
| Serum Response Factor | 1 | 2012 | 2 | 0.100 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2012 | 4 | 0.100 |
Why?
|
| Drug Design | 2 | 2011 | 51 | 0.100 |
Why?
|
| Potassium Chloride | 2 | 2017 | 7 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 156 | 0.100 |
Why?
|
| Amidohydrolases | 1 | 2012 | 9 | 0.100 |
Why?
|
| Receptors, Cholinergic | 1 | 2013 | 26 | 0.100 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2012 | 9 | 0.100 |
Why?
|
| Bacterial Toxins | 1 | 2013 | 22 | 0.100 |
Why?
|
| Microarray Analysis | 2 | 2014 | 20 | 0.100 |
Why?
|
| Apoptosis | 1 | 2015 | 375 | 0.090 |
Why?
|
| Nucleotidyltransferases | 1 | 2012 | 8 | 0.090 |
Why?
|
| Pyrazines | 1 | 2012 | 14 | 0.090 |
Why?
|
| Embryo, Mammalian | 1 | 2012 | 31 | 0.090 |
Why?
|
| Endothelin-1 | 3 | 2016 | 21 | 0.090 |
Why?
|
| Proteins | 1 | 2013 | 149 | 0.090 |
Why?
|
| Methanol | 1 | 2012 | 4 | 0.090 |
Why?
|
| Antibodies, Bispecific | 1 | 2012 | 5 | 0.090 |
Why?
|
| Axons | 1 | 2012 | 35 | 0.090 |
Why?
|
| Anesthesia | 2 | 2010 | 63 | 0.090 |
Why?
|
| Recovery of Function | 2 | 2011 | 238 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 1211 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2015 | 756 | 0.090 |
Why?
|
| Drug Approval | 1 | 2012 | 13 | 0.090 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2012 | 16 | 0.090 |
Why?
|
| Nerve Fibers | 2 | 2002 | 38 | 0.090 |
Why?
|
| Colonic Diseases | 1 | 2012 | 5 | 0.090 |
Why?
|
| Decerebrate State | 1 | 2012 | 2 | 0.090 |
Why?
|
| Sex Factors | 1 | 2014 | 656 | 0.090 |
Why?
|
| Sweden | 2 | 2014 | 16 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 2 | 2013 | 114 | 0.090 |
Why?
|
| beta Catenin | 1 | 2012 | 38 | 0.090 |
Why?
|
| Cricetulus | 2 | 2010 | 21 | 0.090 |
Why?
|
| Mannitol | 1 | 2011 | 2 | 0.090 |
Why?
|
| Freund's Adjuvant | 1 | 2011 | 3 | 0.090 |
Why?
|
| Cricetinae | 2 | 2010 | 51 | 0.090 |
Why?
|
| Deoxyguanosine | 1 | 2011 | 3 | 0.090 |
Why?
|
| Malondialdehyde | 1 | 2011 | 11 | 0.090 |
Why?
|
| Research Design | 1 | 2013 | 316 | 0.090 |
Why?
|
| Protein Multimerization | 1 | 2011 | 25 | 0.090 |
Why?
|
| Matrix Metalloproteinases | 1 | 2011 | 8 | 0.090 |
Why?
|
| Iodine Radioisotopes | 1 | 2011 | 22 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 293 | 0.090 |
Why?
|
| Gastrin-Releasing Peptide | 1 | 2011 | 4 | 0.090 |
Why?
|
| TRPC Cation Channels | 2 | 2008 | 4 | 0.090 |
Why?
|
| Vesico-Ureteral Reflux | 2 | 2008 | 22 | 0.090 |
Why?
|
| Vitamins | 1 | 2012 | 70 | 0.090 |
Why?
|
| Sacrum | 1 | 2011 | 18 | 0.090 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 61 | 0.090 |
Why?
|
| Indium Radioisotopes | 2 | 2013 | 3 | 0.090 |
Why?
|
| Animals, Genetically Modified | 1 | 2011 | 68 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 880 | 0.080 |
Why?
|
| Cost of Illness | 1 | 2011 | 72 | 0.080 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2011 | 8 | 0.080 |
Why?
|
| Anesthesia, General | 1 | 2011 | 30 | 0.080 |
Why?
|
| Rats, Wistar | 4 | 2017 | 111 | 0.080 |
Why?
|
| Tissue Distribution | 5 | 2013 | 64 | 0.080 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2011 | 5 | 0.080 |
Why?
|
| Potassium Channel Blockers | 1 | 2011 | 9 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2011 | 37 | 0.080 |
Why?
|
| Hormone Antagonists | 1 | 2010 | 5 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 43 | 0.080 |
Why?
|
| Isotope Labeling | 1 | 2011 | 14 | 0.080 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2010 | 9 | 0.080 |
Why?
|
| Calmodulin | 1 | 2010 | 3 | 0.080 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2010 | 10 | 0.080 |
Why?
|
| Schwann Cells | 1 | 2010 | 5 | 0.080 |
Why?
|
| Substrate Specificity | 1 | 2011 | 80 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 904 | 0.080 |
Why?
|
| Macaca mulatta | 2 | 2009 | 340 | 0.080 |
Why?
|
| Medial Forebrain Bundle | 1 | 2010 | 2 | 0.080 |
Why?
|
| Adrenergic Agents | 1 | 2010 | 7 | 0.080 |
Why?
|
| Obesity | 1 | 2017 | 1111 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 78 | 0.080 |
Why?
|
| Biopsy | 3 | 2018 | 249 | 0.080 |
Why?
|
| Syndrome | 2 | 2014 | 66 | 0.080 |
Why?
|
| Microinjections | 1 | 2010 | 39 | 0.080 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 109 | 0.080 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 22 | 0.080 |
Why?
|
| Tissue Scaffolds | 1 | 2013 | 431 | 0.080 |
Why?
|
| France | 1 | 2009 | 2 | 0.080 |
Why?
|
| Administration, Topical | 1 | 2010 | 142 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 47 | 0.070 |
Why?
|
| Vasoconstriction | 2 | 2016 | 42 | 0.070 |
Why?
|
| Metabolic Clearance Rate | 2 | 2006 | 18 | 0.070 |
Why?
|
| Impotence, Vasculogenic | 1 | 2009 | 2 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 124 | 0.070 |
Why?
|
| Estrogens | 1 | 2010 | 194 | 0.070 |
Why?
|
| Neurokinin B | 1 | 2009 | 1 | 0.070 |
Why?
|
| Neurokinin A | 1 | 2009 | 1 | 0.070 |
Why?
|
| Hyperkinesis | 1 | 2009 | 8 | 0.070 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2008 | 7 | 0.070 |
Why?
|
| Antidepressive Agents | 1 | 2009 | 73 | 0.070 |
Why?
|
| Calcium Channels, T-Type | 1 | 2009 | 28 | 0.070 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 2 | 2006 | 5 | 0.070 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 179 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 2238 | 0.070 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2009 | 43 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2010 | 178 | 0.070 |
Why?
|
| Finasteride | 1 | 2008 | 4 | 0.070 |
Why?
|
| Natriuretic Peptide, C-Type | 1 | 2008 | 2 | 0.070 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2008 | 10 | 0.070 |
Why?
|
| Injections, Subcutaneous | 2 | 2010 | 36 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2009 | 248 | 0.070 |
Why?
|
| Logistic Models | 3 | 2016 | 743 | 0.070 |
Why?
|
| Analysis of Variance | 4 | 2012 | 471 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2011 | 95 | 0.070 |
Why?
|
| Dietary Proteins | 1 | 2008 | 63 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 821 | 0.070 |
Why?
|
| Myoblasts, Skeletal | 1 | 2008 | 21 | 0.070 |
Why?
|
| Cells, Cultured | 4 | 2013 | 839 | 0.070 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2008 | 86 | 0.070 |
Why?
|
| Genotype | 1 | 2009 | 702 | 0.070 |
Why?
|
| Mutagenesis, Insertional | 1 | 2007 | 17 | 0.070 |
Why?
|
| Oxytocics | 1 | 2008 | 14 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 70 | 0.070 |
Why?
|
| Infertility | 1 | 2007 | 15 | 0.070 |
Why?
|
| United States | 2 | 2009 | 4068 | 0.070 |
Why?
|
| Soybean Proteins | 1 | 2008 | 101 | 0.070 |
Why?
|
| Neoplasms | 1 | 2015 | 757 | 0.070 |
Why?
|
| Mitochondrial Membranes | 1 | 2007 | 27 | 0.070 |
Why?
|
| Bladder Exstrophy | 1 | 2007 | 9 | 0.070 |
Why?
|
| Arginine | 2 | 2010 | 23 | 0.070 |
Why?
|
| Adenosine Triphosphatases | 2 | 2007 | 14 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 113 | 0.070 |
Why?
|
| Iris | 1 | 2007 | 7 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2017 | 3609 | 0.060 |
Why?
|
| Tetrodotoxin | 2 | 2006 | 14 | 0.060 |
Why?
|
| Immunotoxins | 1 | 2007 | 18 | 0.060 |
Why?
|
| Mitochondrial Proteins | 1 | 2007 | 72 | 0.060 |
Why?
|
| Biomedical Engineering | 1 | 2007 | 28 | 0.060 |
Why?
|
| Cardiovascular System | 1 | 2007 | 49 | 0.060 |
Why?
|
| Diabetic Neuropathies | 1 | 2007 | 28 | 0.060 |
Why?
|
| Sensation Disorders | 1 | 2006 | 11 | 0.060 |
Why?
|
| Research | 1 | 2007 | 81 | 0.060 |
Why?
|
| Female Urogenital Diseases | 1 | 2006 | 5 | 0.060 |
Why?
|
| Male Urogenital Diseases | 1 | 2006 | 5 | 0.060 |
Why?
|
| Pentetic Acid | 1 | 2006 | 4 | 0.060 |
Why?
|
| Clitoris | 1 | 2006 | 1 | 0.060 |
Why?
|
| Equipment Failure Analysis | 1 | 2006 | 44 | 0.060 |
Why?
|
| Mast Cells | 1 | 2006 | 13 | 0.060 |
Why?
|
| Arecoline | 1 | 2006 | 3 | 0.060 |
Why?
|
| Muscarinic Agonists | 1 | 2006 | 8 | 0.060 |
Why?
|
| Cholinergic Fibers | 1 | 2006 | 10 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2018 | 309 | 0.060 |
Why?
|
| Interleukin-13 | 1 | 2006 | 29 | 0.060 |
Why?
|
| Cholecalciferol | 1 | 2006 | 25 | 0.060 |
Why?
|
| Guanosine Diphosphate | 1 | 2005 | 4 | 0.060 |
Why?
|
| Thionucleotides | 1 | 2005 | 5 | 0.060 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2005 | 12 | 0.060 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2005 | 35 | 0.060 |
Why?
|
| Mitochondria | 1 | 2007 | 211 | 0.060 |
Why?
|
| Equipment Design | 1 | 2006 | 178 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2005 | 32 | 0.060 |
Why?
|
| Exercise Therapy | 2 | 2018 | 249 | 0.060 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 2005 | 9 | 0.060 |
Why?
|
| Tissue Fixation | 2 | 2016 | 13 | 0.060 |
Why?
|
| Paraffin Embedding | 2 | 2016 | 12 | 0.060 |
Why?
|
| Formaldehyde | 2 | 2016 | 15 | 0.060 |
Why?
|
| Child | 4 | 2018 | 2430 | 0.060 |
Why?
|
| Receptors, Calcitriol | 1 | 2004 | 13 | 0.050 |
Why?
|
| Potassium Channels | 1 | 2004 | 20 | 0.050 |
Why?
|
| Acrolein | 3 | 2010 | 4 | 0.050 |
Why?
|
| Manometry | 1 | 2004 | 22 | 0.050 |
Why?
|
| Metalloendopeptidases | 1 | 2004 | 10 | 0.050 |
Why?
|
| Isothiocyanates | 3 | 2010 | 14 | 0.050 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 2004 | 6 | 0.050 |
Why?
|
| Inflammation | 2 | 2018 | 507 | 0.050 |
Why?
|
| Nervous System | 1 | 2004 | 12 | 0.050 |
Why?
|
| Nuclear Proteins | 2 | 2016 | 74 | 0.050 |
Why?
|
| Rhodamines | 1 | 2004 | 6 | 0.050 |
Why?
|
| Hormones | 1 | 2004 | 24 | 0.050 |
Why?
|
| GABA Agents | 1 | 2004 | 3 | 0.050 |
Why?
|
| Acetates | 1 | 2004 | 14 | 0.050 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2004 | 28 | 0.050 |
Why?
|
| Receptors, Opioid | 1 | 2004 | 14 | 0.050 |
Why?
|
| Critical Pathways | 1 | 2004 | 47 | 0.050 |
Why?
|
| Immunoconjugates | 2 | 2014 | 10 | 0.050 |
Why?
|
| Narcotics | 1 | 2004 | 32 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 81 | 0.050 |
Why?
|
| Surface Plasmon Resonance | 2 | 2015 | 17 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2009 | 1423 | 0.050 |
Why?
|
| Linear Models | 2 | 2016 | 426 | 0.050 |
Why?
|
| Pregnancy | 2 | 2017 | 960 | 0.050 |
Why?
|
| Hypothalamus | 1 | 2003 | 22 | 0.050 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2003 | 12 | 0.050 |
Why?
|
| NADPH Dehydrogenase | 1 | 2003 | 3 | 0.050 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2004 | 80 | 0.050 |
Why?
|
| NADP | 1 | 2003 | 12 | 0.050 |
Why?
|
| Stereoisomerism | 1 | 2003 | 26 | 0.050 |
Why?
|
| Drug Administration Routes | 1 | 2003 | 13 | 0.050 |
Why?
|
| Heptanol | 1 | 2003 | 1 | 0.050 |
Why?
|
| Rats, Inbred Strains | 1 | 2003 | 76 | 0.050 |
Why?
|
| Receptors, Dopamine | 1 | 2003 | 26 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2003 | 18 | 0.050 |
Why?
|
| Muscle Hypertonia | 1 | 2003 | 1 | 0.050 |
Why?
|
| Receptors, Opioid, mu | 1 | 2003 | 36 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2005 | 267 | 0.050 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 2 | 2013 | 6 | 0.050 |
Why?
|
| Naloxone | 1 | 2003 | 32 | 0.050 |
Why?
|
| Morphine | 1 | 2003 | 50 | 0.050 |
Why?
|
| Rats, Inbred Lew | 2 | 2013 | 123 | 0.050 |
Why?
|
| Genetic Engineering | 2 | 2016 | 22 | 0.050 |
Why?
|
| Receptors, Serotonin, 5-HT1 | 1 | 2002 | 1 | 0.050 |
Why?
|
| Baclofen | 1 | 2002 | 26 | 0.050 |
Why?
|
| Hexamethonium | 1 | 2002 | 1 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2005 | 415 | 0.050 |
Why?
|
| Benzophenones | 1 | 2002 | 3 | 0.050 |
Why?
|
| Cats | 1 | 2002 | 135 | 0.050 |
Why?
|
| Thromboxane-A Synthase | 2 | 2013 | 2 | 0.050 |
Why?
|
| Cell Line | 2 | 2014 | 454 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2002 | 66 | 0.050 |
Why?
|
| Benzamides | 1 | 2002 | 60 | 0.050 |
Why?
|
| Japan | 1 | 2002 | 19 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2017 | 1839 | 0.050 |
Why?
|
| Troponin T | 1 | 2003 | 92 | 0.050 |
Why?
|
| Europe | 1 | 2002 | 82 | 0.050 |
Why?
|
| Atropine | 1 | 2002 | 19 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 93 | 0.040 |
Why?
|
| Catheterization, Peripheral | 1 | 2002 | 27 | 0.040 |
Why?
|
| Behavior Therapy | 2 | 2018 | 102 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 150 | 0.040 |
Why?
|
| rhoA GTP-Binding Protein | 2 | 2012 | 13 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2003 | 390 | 0.040 |
Why?
|
| Maleimides | 2 | 2011 | 8 | 0.040 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2019 | 11 | 0.040 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2019 | 27 | 0.040 |
Why?
|
| Catheterization | 2 | 2011 | 55 | 0.040 |
Why?
|
| Immunity, Mucosal | 1 | 2018 | 6 | 0.040 |
Why?
|
| Mucositis | 1 | 2018 | 10 | 0.040 |
Why?
|
| Rats, Inbred WKY | 2 | 2010 | 21 | 0.040 |
Why?
|
| Breath Tests | 1 | 2018 | 18 | 0.030 |
Why?
|
| Metabolomics | 1 | 2019 | 63 | 0.030 |
Why?
|
| Phagosomes | 1 | 2018 | 6 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 42 | 0.030 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2018 | 10 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2018 | 46 | 0.030 |
Why?
|
| Behavior, Addictive | 1 | 2018 | 40 | 0.030 |
Why?
|
| Phenotype | 2 | 2014 | 622 | 0.030 |
Why?
|
| Neutrophils | 1 | 2018 | 120 | 0.030 |
Why?
|
| Electromagnetic Fields | 1 | 2017 | 26 | 0.030 |
Why?
|
| Physical Therapy Modalities | 1 | 2018 | 81 | 0.030 |
Why?
|
| Pregnancy, Animal | 1 | 2017 | 20 | 0.030 |
Why?
|
| Self Care | 1 | 2018 | 97 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2017 | 96 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 286 | 0.030 |
Why?
|
| Muscle Development | 1 | 2017 | 52 | 0.030 |
Why?
|
| Microsurgery | 1 | 2017 | 20 | 0.030 |
Why?
|
| Ethylene Oxide | 1 | 2017 | 1 | 0.030 |
Why?
|
| Animals, Newborn | 2 | 2009 | 136 | 0.030 |
Why?
|
| Lactones | 1 | 2017 | 13 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2017 | 20 | 0.030 |
Why?
|
| Compliance | 1 | 2017 | 14 | 0.030 |
Why?
|
| Gonadotropins | 1 | 2016 | 5 | 0.030 |
Why?
|
| Thyroid Hormones | 1 | 2016 | 7 | 0.030 |
Why?
|
| Macrophages | 1 | 2018 | 207 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2005 | 1437 | 0.030 |
Why?
|
| HLA-A2 Antigen | 1 | 2016 | 6 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2016 | 10 | 0.030 |
Why?
|
| Telemedicine | 1 | 2018 | 122 | 0.030 |
Why?
|
| Viral Matrix Proteins | 1 | 2016 | 12 | 0.030 |
Why?
|
| Surgical Mesh | 1 | 2017 | 50 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2016 | 17 | 0.030 |
Why?
|
| Testosterone | 1 | 2016 | 48 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2016 | 54 | 0.030 |
Why?
|
| Prostatitis | 1 | 2016 | 4 | 0.030 |
Why?
|
| Dinoprost | 1 | 2016 | 9 | 0.030 |
Why?
|
| Cell Transdifferentiation | 1 | 2016 | 7 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 2016 | 32 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 94 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 255 | 0.030 |
Why?
|
| Peptides | 1 | 2016 | 127 | 0.030 |
Why?
|
| Uterus | 1 | 2016 | 77 | 0.030 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2015 | 65 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2015 | 110 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2014 | 14 | 0.030 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 2 | 2006 | 4 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 476 | 0.030 |
Why?
|
| Heterocyclic Compounds, Bridged-Ring | 1 | 2014 | 1 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2006 | 359 | 0.030 |
Why?
|
| Myosin Light Chains | 1 | 2014 | 5 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2016 | 140 | 0.030 |
Why?
|
| Quinolones | 1 | 2014 | 7 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2014 | 17 | 0.030 |
Why?
|
| Quinolizines | 1 | 2014 | 3 | 0.030 |
Why?
|
| Artifacts | 1 | 2014 | 45 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 164 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 458 | 0.030 |
Why?
|
| Cystoscopy | 1 | 2014 | 27 | 0.030 |
Why?
|
| Nasopharynx | 1 | 2013 | 9 | 0.030 |
Why?
|
| Radioactive Tracers | 1 | 2013 | 1 | 0.030 |
Why?
|
| Receptors, Neuropeptide Y | 1 | 2013 | 2 | 0.030 |
Why?
|
| Peptide YY | 1 | 2013 | 2 | 0.030 |
Why?
|
| Cell Survival | 1 | 2014 | 286 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2014 | 183 | 0.020 |
Why?
|
| Testis | 1 | 2013 | 71 | 0.020 |
Why?
|
| Transfection | 1 | 2013 | 204 | 0.020 |
Why?
|
| Opossums | 1 | 2013 | 3 | 0.020 |
Why?
|
| Muscles | 1 | 2013 | 69 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2013 | 57 | 0.020 |
Why?
|
| Purines | 1 | 2013 | 21 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2013 | 20 | 0.020 |
Why?
|
| Agrin | 1 | 2013 | 9 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2013 | 64 | 0.020 |
Why?
|
| Isoproterenol | 1 | 2012 | 17 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 26 | 0.020 |
Why?
|
| Drug Stability | 1 | 2012 | 11 | 0.020 |
Why?
|
| Molecular Imaging | 1 | 2013 | 18 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2013 | 100 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2012 | 34 | 0.020 |
Why?
|
| DNA Transposable Elements | 1 | 2012 | 16 | 0.020 |
Why?
|
| Myocardium | 1 | 2013 | 184 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2012 | 43 | 0.020 |
Why?
|
| Electrochemical Techniques | 1 | 2012 | 26 | 0.020 |
Why?
|
| Hindlimb | 1 | 2012 | 53 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 60 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2012 | 27 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2012 | 110 | 0.020 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2012 | 10 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 132 | 0.020 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 2012 | 7 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2012 | 83 | 0.020 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2012 | 21 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 97 | 0.020 |
Why?
|
| Calcium Channels, L-Type | 1 | 2012 | 46 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 90 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2011 | 16 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 112 | 0.020 |
Why?
|
| Cell Shape | 1 | 2011 | 28 | 0.020 |
Why?
|
| G-Protein-Coupled Receptor Kinase 1 | 1 | 2011 | 1 | 0.020 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2011 | 5 | 0.020 |
Why?
|
| Isoquinolines | 1 | 2011 | 8 | 0.020 |
Why?
|
| Butadienes | 1 | 2011 | 9 | 0.020 |
Why?
|
| Nitriles | 1 | 2011 | 24 | 0.020 |
Why?
|
| Luteinizing Hormone | 1 | 2010 | 16 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2011 | 40 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2010 | 30 | 0.020 |
Why?
|
| Libido | 1 | 2010 | 5 | 0.020 |
Why?
|
| CHO Cells | 1 | 2010 | 29 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 47 | 0.020 |
Why?
|
| Abdominal Cavity | 1 | 2010 | 6 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 90 | 0.020 |
Why?
|
| Transducers, Pressure | 1 | 2010 | 2 | 0.020 |
Why?
|
| Action Potentials | 1 | 2011 | 212 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 2010 | 62 | 0.020 |
Why?
|
| Indomethacin | 1 | 2010 | 7 | 0.020 |
Why?
|
| Cyclohexanols | 1 | 2010 | 22 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 128 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2010 | 47 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2010 | 23 | 0.020 |
Why?
|
| N-Methylaspartate | 1 | 2010 | 13 | 0.020 |
Why?
|
| Radiography | 1 | 2010 | 358 | 0.020 |
Why?
|
| Polyunsaturated Alkamides | 1 | 2009 | 13 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 99 | 0.020 |
Why?
|
| Arachidonic Acids | 1 | 2009 | 29 | 0.020 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2008 | 2 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2008 | 42 | 0.020 |
Why?
|
| Guanylate Cyclase | 1 | 2008 | 9 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2010 | 171 | 0.020 |
Why?
|
| Abdomen | 1 | 2009 | 44 | 0.020 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 2008 | 17 | 0.020 |
Why?
|
| Endocannabinoids | 1 | 2009 | 44 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2008 | 42 | 0.020 |
Why?
|
| Guided Tissue Regeneration | 1 | 2008 | 39 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 155 | 0.020 |
Why?
|
| Dogs | 1 | 2008 | 125 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2011 | 189 | 0.020 |
Why?
|
| Infant | 1 | 2011 | 1010 | 0.020 |
Why?
|
| Sulfides | 1 | 2008 | 27 | 0.020 |
Why?
|
| Myosin-Light-Chain Phosphatase | 1 | 2008 | 3 | 0.020 |
Why?
|
| Abdominal Muscles | 1 | 2008 | 6 | 0.020 |
Why?
|
| Ovulation | 1 | 2007 | 8 | 0.020 |
Why?
|
| Ankyrins | 1 | 2007 | 1 | 0.020 |
Why?
|
| Hydrogen Sulfide | 1 | 2007 | 4 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2011 | 1233 | 0.020 |
Why?
|
| Ovarian Follicle | 1 | 2007 | 36 | 0.020 |
Why?
|
| Molecular Biology | 1 | 2007 | 8 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 257 | 0.020 |
Why?
|
| Actins | 1 | 2007 | 54 | 0.020 |
Why?
|
| Epithelium | 1 | 2006 | 22 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2007 | 60 | 0.020 |
Why?
|
| Forensic Pathology | 1 | 2006 | 11 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2007 | 114 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2006 | 55 | 0.020 |
Why?
|
| Cadaver | 1 | 2006 | 151 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2006 | 2 | 0.020 |
Why?
|
| Chloral Hydrate | 1 | 2006 | 2 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2007 | 285 | 0.020 |
Why?
|
| Anesthetics, Intravenous | 1 | 2006 | 18 | 0.010 |
Why?
|
| Nifedipine | 1 | 2006 | 10 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2006 | 73 | 0.010 |
Why?
|
| Sexuality | 1 | 2006 | 14 | 0.010 |
Why?
|
| Scopolamine | 1 | 2006 | 8 | 0.010 |
Why?
|
| Mechanoreceptors | 1 | 2006 | 31 | 0.010 |
Why?
|
| Dihydrotestosterone | 1 | 2005 | 4 | 0.010 |
Why?
|
| Estrone | 1 | 2005 | 13 | 0.010 |
Why?
|
| Orchiectomy | 1 | 2005 | 14 | 0.010 |
Why?
|
| Radioimmunotherapy | 1 | 2005 | 2 | 0.010 |
Why?
|
| Guanosine | 1 | 2005 | 2 | 0.010 |
Why?
|
| Myography | 1 | 2005 | 7 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2006 | 290 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2005 | 80 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2007 | 666 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 221 | 0.010 |
Why?
|
| Muscular Diseases | 1 | 2005 | 23 | 0.010 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2004 | 4 | 0.010 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2004 | 5 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2005 | 46 | 0.010 |
Why?
|
| International Cooperation | 1 | 2004 | 31 | 0.010 |
Why?
|
| Domperidone | 1 | 2004 | 1 | 0.010 |
Why?
|
| Receptors, Dopamine D4 | 1 | 2004 | 7 | 0.010 |
Why?
|
| Haloperidol | 1 | 2004 | 15 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2004 | 91 | 0.010 |
Why?
|
| Anxiety | 1 | 2005 | 195 | 0.010 |
Why?
|
| Consensus | 1 | 2004 | 87 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2003 | 20 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2003 | 48 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 264 | 0.010 |
Why?
|
| Connective Tissue | 1 | 2003 | 4 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2003 | 43 | 0.010 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2002 | 9 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2003 | 119 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 215 | 0.010 |
Why?
|
| Algorithms | 1 | 2004 | 536 | 0.010 |
Why?
|